SMTI (Sanara MedTech) Change In Receivables: $-0.9 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SMTI Sanara MedTech Inc SMTI
80 GF Score
Price $34.45
GF Value $43.37
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Sanara MedTech Change In Receivables?

Sanara MedTech SMTI +0.55% 80 Change In Receivables is $-0.9 Mil as of Jun. 2026. GuruFocus rates SMTI with a GF Score™ of 80/100 and a GF Value™ of $43.37 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Sanara MedTech's change in receivables for the quarter that ended in Jun. 2026 was $1.0 Mil. It means Sanara MedTech's Accounts Receivable declined by $1.0 Mil from Mar. 2026 to Jun. 2026 .

Sanara MedTech's change in receivables for the fiscal year that ended in Dec. 2025 was $-0.1 Mil. It means Sanara MedTech's Accounts Receivable increased by $0.1 Mil from Dec. 2024 to Dec. 2025 .

Sanara MedTech's Accounts Receivable for the quarter that ended in Jun. 2026 was $12.6 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Sanara MedTech's Days Sales Outstanding for the three months ended in Jun. 2026 was 40.78.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Sanara MedTech's liquidation value for the three months ended in Jun. 2026 was $-34.6 Mil.

Sanara MedTech  (NAS:SMTI) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Sanara MedTech's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=12.573/28.137*91
=40.78

2. In Ben Graham's calculation of liquidation value, Sanara MedTech's accounts receivable are only considered to be worth 75% of book value:

Sanara MedTech's liquidation value for the quarter that ended in Jun. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=15.421-61.212+0.75 * 12.573+0.5 * 3.46
=-34.6

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sanara MedTech Change In Receivables Related Terms

Sanara MedTech Change In Receivables Historical Data

* Premium members only.

The historical data trend for Sanara MedTech's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sanara MedTech Change In Receivables Chart

Sanara MedTech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.78 -2.27 -1.73 -4.54 -0.07

Sanara MedTech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.21 -0.26 0.03 -1.71 1.01
SMTI
80GF Score
Sanara MedTech Inc SMTI
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sanara MedTech Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $-0.9 Mil mean?
Sanara MedTech (SMTI) has a Change In Receivables of $-0.9 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Sanara MedTech and its competitors.
Is Sanara MedTech's Change In Receivables too high?
Sanara MedTech's current Change In Receivables is $-0.9 Mil. Overall, Sanara MedTech has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sanara MedTech's Change In Receivables compare to UTMD and OSUR?
Sanara MedTech's Change In Receivables of $-0.9 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Medical Devices & Instruments company?
A good Change In Receivables depends on the Medical Devices & Instruments industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Sanara MedTech and its competitors. Sanara MedTech's current Change In Receivables is $-0.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanara MedTech stock overvalued right now?
Based on GuruFocus' analysis, Sanara MedTech (SMTI) is currently considered Modestly Undervalued. The stock's GF Value™ is $43.37, compared to a current price of $34.45 — trading 20.6% below its estimated fair value. The current Change In Receivables is $-0.9 Mil. Sanara MedTech's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Sanara MedTech (SMTI), the current Change In Receivables is $-0.9 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sanara MedTech (SMTI) Overvalued in 2026?

Based on GuruFocus' analysis, Sanara MedTech stock appears to be undervalued. The current stock price of $34.45 is trading 20.6% below its estimated GF Value™ of $43.37. GuruFocus considers Sanara MedTech to be Modestly Undervalued.

Key valuation signals for SMTI:

  • Change In Receivables: $-0.9 Mil
  • GF Value™: $43.37 vs. price of $34.45 (20.6% below fair value)
  • GF Score™: 80/100 with 5 warning signs

No single metric tells the full story. See the SMTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sanara MedTech Business Description

Address 1200 Summit Avenue, Suite 414, Fort Worth, TX, USA, 76102
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.
80GF Score

Get the complete analysis for SMTI

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$34.45
Price
$43.37
GF Value